Key Points
- Grace Wong-Sarad, an insider at Alector (NASDAQ:ALEC), sold 4,079 shares on Feb 26 at an average price of $2.50 for $10,197.50, trimming her stake to 118,903 shares (a 3.32% reduction); she also sold 4,753 and 8,056 shares in early December.
- ALEC shares traded down about 4.5% to $2.45 with a market cap of ~$267 million; the company reported Q4 EPS of -$0.34 (beating -$0.39) and revenue of $6.24M (vs. $1.78M expected), but remains unprofitable with a negative P/E.
- Analysts are mixed with an average rating of "Hold" and an average target price of $3.25, while institutional investors own roughly 85.8% of the stock.
Alector, Inc. (NASDAQ:ALEC - Get Free Report) insider Grace Wong-Sarad sold 4,079 shares of the business's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $2.50, for a total transaction of $10,197.50. Following the sale, the insider owned 118,903 shares in the company, valued at $297,257.50. This represents a 3.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Grace Wong-Sarad also recently made the following trade(s):
- On Friday, December 5th, Grace Wong-Sarad sold 4,753 shares of Alector stock. The stock was sold at an average price of $1.21, for a total transaction of $5,751.13.
- On Wednesday, December 3rd, Grace Wong-Sarad sold 8,056 shares of Alector stock. The stock was sold at an average price of $1.12, for a total transaction of $9,022.72.
Alector Stock Down 4.5%
NASDAQ:ALEC traded down $0.12 during trading hours on Friday, hitting $2.45. 110,713 shares of the stock traded hands, compared to its average volume of 917,617. The firm has a 50 day moving average price of $1.83 and a 200 day moving average price of $2.03. The firm has a market cap of $266.87 million, a price-to-earnings ratio of -1.76 and a beta of 0.64. Alector, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $3.40. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.17.
Alector (NASDAQ:ALEC - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.05. The business had revenue of $6.24 million during the quarter, compared to analysts' expectations of $1.78 million. Alector had a negative return on equity of 191.85% and a negative net margin of 679.16%. Equities research analysts anticipate that Alector, Inc. will post -1.88 earnings per share for the current year.
Analyst Upgrades and Downgrades
ALEC has been the subject of a number of research reports. Wall Street Zen raised Alector from a "sell" rating to a "hold" rating in a research report on Saturday, February 21st. BTIG Research raised Alector from a "hold" rating to a "strong-buy" rating in a research note on Monday, January 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alector in a report on Wednesday, January 21st. Finally, Morgan Stanley reissued an "underweight" rating on shares of Alector in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $3.25.
Read Our Latest Report on ALEC
Institutional Trading of Alector
Several large investors have recently made changes to their positions in ALEC. Bank of America Corp DE boosted its position in shares of Alector by 1.8% in the second quarter. Bank of America Corp DE now owns 343,909 shares of the company's stock valued at $481,000 after acquiring an additional 5,927 shares during the period. Los Angeles Capital Management LLC raised its stake in Alector by 5.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 151,896 shares of the company's stock valued at $213,000 after purchasing an additional 7,600 shares during the last quarter. Sio Capital Management LLC raised its stake in Alector by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 845,531 shares of the company's stock valued at $1,184,000 after purchasing an additional 8,372 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Alector by 3.4% in the 3rd quarter. Mackenzie Financial Corp now owns 283,712 shares of the company's stock valued at $840,000 after purchasing an additional 9,270 shares during the period. Finally, Lexington Partners L.P. acquired a new stake in Alector in the 3rd quarter worth $30,000. Institutional investors own 85.83% of the company's stock.
About Alector
(
Get Free Report)
Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector's approach aims to harness the body's natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer's disease and frontotemporal dementia.
The company's pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer's disease studies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
